Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | STK16 | O75716 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17937465 | 1.00 | IRAK4 (0.42) | IRAK4SMYD3SYKDAPK3JAK2 | |
| SCHEMBL1709800 | 0.84 | IRAK4 (0.49) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL20261991 | 0.81 | IRAK4 (0.55) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL20261989 | 0.81 | IRAK4 (0.55) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL3712626 | 0.79 | IRAK4 (0.44) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL16595153 | 0.78 | IRAK4 (0.44) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL20273951 | 0.78 | KMT2A (0.47) | IRAK4SYKDAPK3JAK2STK16 | |
| SCHEMBL16595166 | 0.78 | IRAK4 (0.46) | IRAK4JAK2PAK4ABL1LCK | |
| SCHEMBL17937488 | 0.78 | IRAK4 (0.46) | IRAK4JAK2PAK4ABL1LCK | |
| SCHEMBL16595542 | 0.78 | JAK3 (0.44) | IRAK4SMYD3TEAD1BTKMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
| EP-3048105-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048105-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039612-A1 | COMPOUND INHIBITING KINASE ACTIVITIES OF BTK AND/OR JAK3 | 北京韩美药品有限公司 | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | IRAK4 101/4885SMYD3 769/4885SYK 5/4885 |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | IRAK4 101/4885SMYD3 769/4885SYK 5/4885 |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | BTK, JAK3, JAK2 | IRAK4 101/4885SMYD3 769/4885SYK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.